$7.39 -$0.29 (-3.8%)

02:07 PM EST on 02/19/20

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS)

CAPS Rating: No stars

Current Price $7.39 Mkt Cap $325.9M
Open $7.70 P/E Ratio 0.00
Prev. Close $7.68 Div. (Yield) $0.00 (0.0%)
Daily Range $7.14 - $7.71 Volume 124,338
52-Wk Range $6.67 - $9.41 Avg. Daily Vol. 299,948

Caps

How do you think NASDAQ:SYRS will perform against the market?

Add Stock to CAPS Watchlist

All Players

1 Outperform
1 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SYRS Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

SmartAce (99.97)
Submitted March 18, 2019

I miss those two years in the nineties when instead of using sarcasm we’d just say the opposite of what we were thinking followed by “NOT”

NASDAQ:SYRS VS S&P 500 (SPY)

NASDAQ:SYRS Summary

Fools bullish on NASDAQ:SYRS are also bullish on:

Fools bearish on NASDAQ:SYRS are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about SYRS.

Recs

0
Member Avatar mdriver78 (70.30) Submitted: 1/24/2020 9:03:31 AM : Outperform Start Price: $7.66 NASDAQ:SYRS Score: -5.90

Potential big winner in treating blood cancers like acute myeloid leukemia (AML). The company is on track to report Phase 2 data from its AML program later this year.

Good results could send SYRS shares soaring.

In the meantime, however, the GBT partnership news is sending SYRS shares up sharply over the past month.

Syros’ therapies, like its AML drug called SY-1425, work by controlling how genes are expressed. In cancer, this could be a very valuable approach, since shutting down cancer genes could help create new treatments.

But Syros’ gene expression platform could be broadly applicable to other types of disease including sickle cell disease and beta thalassemia.

Global Blood Therapeutics wants to tap into Syros’ drug discovery engine to find new targets and leads, with a primary interest in finding a way to induce the production of fetal hemoglobin through an oral drug.

Success means GBT will gain exclusive license to develop these leads into commercial therapies, potentially producing a functional cure. For Syros, success is a $20 million upfront payment, access to future milestone payments and three years of preclinical research payments.

Leaderboard

Find the members with the highest scoring picks in SYRS.

Score Leader

chushogi

chushogi (67.31) Score: +91.89

The Score Leader is the player with the highest score across all their picks in SYRS.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
chushogi 67.31 1/9/2017 Underperform 5Y $12.86 -42.61% +49.28% +91.89 0 Comment
mdriver78 70.30 1/24/2020 Outperform 5Y $7.66 -3.66% +2.25% -5.90 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SYRS.